Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.

Journal of clinical pharmacy and therapeutics - 1 Feb 2006

Ismail R, Teh L K

Abstract excerpt

BACKGROUND AND OBJECTIVE: CYP2D6 polymorphisms are well described in normal populations but there are few data on its clinical significance. We therefore investigated the influence of CYP2D6 polymorphism on steady-state plasma concentrations and apparent oral clearance of metoprolol in patients with cardiovascular diseases. METHODS: Ninety-one patients on metoprolol were recruited. Plasma concentrations of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Anti-Arrhythmia Agents
Share to Antihypertensive Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cardiovascular Diseases

Share to Cytochrome P-450 CYP2D6

Share to Kidney Diseases

Share to Metoprolol

Share to Pharmacogenetics

Source

Identifiers

PMID: 16476126
DOI: 10.1111/j.1365-2710.2006.00699.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.PMID 16476126Read ↗

Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug.Semantic proximity Read ↗

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

Cytochrome P450 2D6 phenotype and genotype in hypertensive patients on long-term therapy with metoprolol.Semantic proximity Read ↗

Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.Semantic proximity Read ↗

Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes.Semantic proximity Read ↗

The relationship between plasma concentration of metoprolol and CYP2D6 genotype in patients with ischemic heart disease.Semantic proximity Read ↗

Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment.Semantic proximity Read ↗

Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.Semantic proximity Read ↗

Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study.Semantic proximity Read ↗

CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis.Semantic proximity Read ↗

Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study.Semantic proximity Read ↗

CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.